These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 26036947)

  • 1. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.
    Eder S; Dubischar-Kastner K; Firbas C; Jelinek T; Jilma B; Kaltenboeck A; Knappik M; Kollaritsch H; Kundi M; Paulke-Korinek M; Schuller E; Klade CS
    Vaccine; 2011 Mar; 29(14):2607-12. PubMed ID: 21288804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.
    Dubischar-Kastner K; Eder S; Buerger V; Gartner-Woelfl G; Kaltenboeck A; Schuller E; Tauber E; Klade C
    Vaccine; 2010 Jul; 28(32):5197-202. PubMed ID: 20541581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.
    Reisler RB; Danner DK; Gibbs PH
    Vaccine; 2010 Mar; 28(12):2436-41. PubMed ID: 20060946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
    Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
    Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A
    Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.
    Erra EO; Askling HH; Rombo L; Riutta J; Vene S; Yoksan S; Lindquist L; Pakkanen SH; Huhtamo E; Vapalahti O; Kantele A
    Clin Infect Dis; 2012 Sep; 55(6):825-34. PubMed ID: 22696017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.
    Chotpitayasunondh T; Suntarattiwong P; Yoksan S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2407663. PubMed ID: 39353860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
    Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
    Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
    Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.